Clinical Trial of All-trans-retinoic Acid, Bevacizumab, and Atezolizumab in Colorectal Cancer

Inclusion Criteria

• Diagnosed with stage IV colon cancer that has spread, confirmed by lab tests.
• Tumors must be from the colon, including those affecting the small bowel.
• Must have specific genetic markers related to DNA repair or stability.
• Have received at least two different chemotherapy treatments for metastatic cancer, including specific drugs unless not medically possible.
• Be 18 years or older.
• Be in good general health with a performance status score of 0 to 2.
• Have adequate organ and bone marrow function, as shown by specific blood tests.
• Negative HIV test, unless stable on treatment with a controlled viral load.
• Negative hepatitis B and C tests.
• Understand and agree to sign a consent form.
• Agree to use effective birth control during the study and for 6 months after treatment.
• Women must not be pregnant and must agree to a pregnancy test before starting treatment.

Exclusion Criteria

• Have a type of colorectal cancer with specific genetic instability.
• Have active autoimmune diseases or conditions requiring high doses of steroids.
• Have used Atezolizumab or ATRA before.
• Have had recent cancer treatments within 3 weeks before starting the study.
• Have untreated brain metastases.
• Have severe allergies to similar drugs used in the study.
• Have uncontrolled high blood pressure or significant heart disease.
• Have serious infections or other illnesses that could affect safety.
• Be pregnant or breastfeeding.
• Have had recent major surgery or plan to have surgery during the study.
• Have active hepatitis B or C, tuberculosis, or uncontrolled HIV.